Nuvilex Inc. (NASDAQ:PMCB) Sees Significant Drop in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 635,629 shares, a decrease of 31.3% from the November 30th total of 925,578 shares. Approximately 10.4% of the shares of the stock are sold short. Based on an average daily volume of 12,965,578 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 12,965,578 shares, the short-interest ratio is currently 0.0 days. Approximately 10.4% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Nuvilex Stock Performance

Shares of NASDAQ:PMCB remained flat at $0.72 during mid-day trading on Wednesday. 291,543 shares of the company were exchanged, compared to its average volume of 874,656. The company has a market cap of $7.30 million, a price-to-earnings ratio of -0.52 and a beta of 0.07. The stock has a fifty day moving average of $0.87 and a 200 day moving average of $0.96. Nuvilex has a 1-year low of $0.63 and a 1-year high of $1.90.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.